Apama Medical is another collaboration between Shifamed LLC and Incept LLC focusing on the development of a novel percutaneous catheters the rapidly growing electrophysiology (EP) market in which mapping and ablation is estimated to reach $2.0B in 2017.
Axtria provides their clients consulting support and customized analytics software to unlock value from data and drive business performance. They take a consultative and collaborative approach to developing analytics solutions, customizing each to the client’s specific business need. They deliver solutions as software tools, leveraging the latest technology and industry-tuned analytics engines. Axtria continuously refines and develops the underlying analytics engines.
Maya Medical – Acquired by Covidien Ltd. (NYSE: COV) in 2012. Maya Medical is a collaboration between Shifamed LLC and Incept LLC focusing on the development of a novel percutaneous catheter for treatment of hypertension, a growing market burdened by a staggering proportion of patients who are unable to effectively control their blood pressure. For uncontrolled /drug-resistant hypertension, the recent emergence of device based therapies is offering patients new hope. By addressing fundamental barriers to current pharmacological and device based therapies, Maya is poised to further enable and accelerate the paradigm shift in the management of uncontrolled hypertension.
Claret Medical is a privately-held company focused on development of a novel technology for stroke prevention during Trans Vascular Aortic Intervention (TAVI) and other structural heart interventions. The company’s first product, the Montage Protection System, has been demonstrated to be safe and effective in removing embolic debris in a clinical study conducted in Europe and Latin America, through which it received approval to commercialize the Montage system outside of the United States.
Hotspur Technologies – Acquired by Teleflex, Inc. (NYSE: TFX) in 2012. Hotspur Technologies was founded to improve patient care by providing a complete and efficacious solution for catheter-mediated therapies for dialysis access interventions.
NextPlane is the leading provider of enterprise-class federation solutions for unified communication (UC) platforms, including Microsoft OCS 2007 R2, OCS 2007 & LCS 2005, IBM Sametime, Cisco Jabber XCP, Cisco WebEx Connect, Cisco Unified Presence Server 8.0, Jive OpenFire, and Google Apps. NextPlane’s enables presence-aware collaboration and communication beyond what unified communication (UC) platforms permit. NextPlane Federation Server (NxPFS) delivers enterprise level connectivity between disparate UC platforms, allowing users from different organizations – even different companies – to work together as if they were served by the same UC platform, by providing full fidelity instant messaging, accurately exchange presence states. Globally 1000 companies are deploying the NextPlane Federation Server or subscribing to the NextPlane Federation Cloud to enable employees across different internal organizations.
Augmenix, Inc., Waltham, MAAugmenix, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers. Augmenix’s vision is to address unmet patient needs following cancer radiotherapy in a variety of organ systems by developing first-of-a-kind therapeutic products based on proprietary in-situ formed hydrogel technology.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis, and dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases.Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Ostial is a privately held medical device company located in Mountain View, CA. The Company is developing a unique, flared stent technology tailored to the specific anatomy and interventional challenges that present at aorto-ostial junctions. The Company’s initial product offering, the BullsEye Ostial Stent System, couples Ostial’s unique stent technology with an intuitive ostial locating-balloon delivery system that enables rapid, precise placement and optimizes stent contouring to the funnel-shaped ostial anatomy.
Sadra Medical, Inc. – Acquired by Boston Scientific (NYSE: BSX) in 2010. – Minimally invasive aortic heart valves placed percutaneously via catheter. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass.
AccessClosure is a privately held medical device company that is pioneering innovative access site management products designed to address the complex challenge of vascular closure during interventional and diagnostic procedures. Our first product, the Mynx vascular closure device, is based on a conformable, water soluble polyethylene glycol (PEG) sealant that instantly expands in the tissue tract by rapidly absorbing blood and subcutaneous fluids. The sealant then dissolves within 30 days, leaving nothing behind but a healed artery. Mynx has been authorized for CE Mark and received FDA approval on May 16, 2007.
Acquired in 2007 by Cognizant Technology Solutions Corporation (NASDAQ: CTSH). MarketRx is a leading provider of specialized Sales and Marketing Effectiveness solutions to global pharmaceutical and biotechnology companies. We combine in-depth domain expertise with proprietary, state-of-the-art analytical models and processes, enabled by world-class technology. We offer completely scalable, web-based global solutions in sales and marketing tracking, analysis, planning and forecasting as well as quick turnaround market research. marketRx team has proven experience in delivering actionable results for over 50 top-tier pharmaceutical companies in all therapeutic areas and across geographies.
QT Vascular is a global company engaged in the development and commercialization of innovative devices for the minimally invasive treatment of vascular disease without the use of permanent implants (stents). (Formerly TriReme Medical, Inc.)
Nellix, Inc. / Endologix Inc., Palo Alto, CA
Nellix, Inc. – Acquired by Endologix Inc. (NASDAQ: ELGX) in 2010, Nellix, Inc., is a medical device company developing novel solutions to abdominal aortic and other aneurysms within the vascular system using an in situ formed PEG. Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a leading cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA.
Embolic Protection, Inc. / Boston Scientific, Inc.
Embolic Protection, Inc. – Acquired by Boston Scientific Corporation (NYSE: BSX) in 2001. Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures.
Confluent Surgical, Inc. – Acquired by Covidien Ltd. (NYSE: COV) in 2006. Confluent Surgical, Inc is a wholly owned subsidiary of U.S Surgical, a Covidien Company and a leading innovator in the development and commercialization of biomaterials that address intra-operative and post-operative complications. Confluent’s technology platform focuses on four segments within the Biosurgical business including sealants, adhesion barriers, internal and external adhesives, and hemostatic agents. Confluent’s flagship product, DuraSeal® Dural Sealant, is the first and only approved cranial dural sealant. Confluent Surgical’s DuraSeal Xact®Adhesion Barrier and Sealant System, approved for use in the European Union and currently under clinical investigation in the United States, is the only dual-function hydrogel approved for spinal applications.